Because GHK-Cu appears frequently in copper peptide research discussions and catalog references, this product may be compared with related research peptides and blends to evaluate similarities and differences in pathway behavior, molecular structure, cellular response, peptide-metal complex signaling, and structure-function relationships
First, GHK-Cu is not a licensed medicine in the UK and there is no regulator-approved dosing schedule
But diagnosis itself is a problem, with average delays of 7 to 10 years between symptom onset and confirmation
Neuroscience (2017) 352:15569
Different patient populations, different enrollment criteria, different sites, and different measurement protocols all introduce variability that makes direct numerical comparison imprecise
doi: 10.1016/j.cell.2015.07.047 210 PearsonR